X

Trial Profile

A Phase 1b, Open Label, Clinical Trial to Evaluate ProTrans in COVID-19 Patients

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 29 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mesenchymal-stem-cell-therapy NextCell-Pharma (Primary)
Indications COVID 2019 infections
Focus Adverse reactions

Most Recent Events

29 Oct 2020 New trial record
21 Oct 2020 According to a NextCell Pharma media release, the clinical trial protocol is written by Professor Dominique Farge, St. Louis Hospital in France, and Doctor Lindsay Davies, CSO NextCell Pharma. The steering committee is Professor Farge (chair), Professor Edvard Smith (NextCell Pharma) and Doctor Tomasz Oldak (PBKM). NextCell decided to subcontract PBKM (FamiCord Group) as Contracted Manufacturing Partner.
21 Oct 2020 According to a NextCell Pharma media release, the principle investigator for this trial is Professor Josefin Sundh, University Hospital Orebro.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com